RxDoctor Payments Data

Anupama Chauhan, MD

Rheumatology · Columbus, OHNPI 1891906566

Payments from drug & device makers

$8,031in general payments, 2019–2025

Across 545 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Johnson & Johnson$1K
  • Novartis$1K
  • Mediview XR, Inc.$1K
  • Pfizer$368
  • plus $753 from 7 others

What the payments were for

  • Travel & lodging$87711%
  • Food & beverage$6,93186%
  • Education$2243%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie169$2,203
Amgen(2 entities)132$1,306
Johnson & Johnson68$1,242
Novartis85$1,104
Mediview XR, Inc.4$1,055
Pfizer33$368
Genentech USA, Inc.33$314
GSK10$184
UCB, Inc.6$170
Octapharma USA, Inc.2$37
AstraZeneca1$22
Mallinckrodt Enterprises LLC1$14
Neurometrix Inc1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,031 in reported general payments places this provider in the 65th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,392,559
Medicare patients
440
Services billed
76,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab41$466,083
Enbrel SureclickEtanercept27$242,911
EnbrelEtanercept16$115,445
Xeljanz XrTofacitinib Citrate16$101,674
MethotrexateMethotrexate Sodium732$25,803
Hydroxychloroquine Sulfate426$19,235
Leflunomide161$9,502
Sulfasalazine DrSulfasalazine136$6,918
Celecoxib141$6,656
Duloxetine Hcl130$5,042
Gabapentin185$3,665
Cevimeline Hcl15$3,351
Prednisone455$2,988
Pilocarpine Hcl34$2,988
Colchicine16$2,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$1,306$115,44516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →